Pathology of Urinary Bladder Inverted Papilloma 

  • Author: Joseph Eaton, DO; Chief Editor: Liang Cheng, MD   more...
 
Updated: Apr 20, 2010
 

Definition

A rare yet benign neoplasm, the inverted papilloma is an endophytic urothelial tumor of moderate significance due to its variable similarity to inverted urothelial carcinoma, which holds a much more aggressive prognosis. The term inverted papilloma was first introduced by Potts & Hirst in 1963,[1] although originally Paschkis described the entity in the bladder in 1927,[2] calling it a polypoid adenoma. The term Brunnian adenoma has also been used, as the lesion bears a modest resemblance to normal Brunn's nests.

The key histologic criteria that separate this benign lesion from its malignant counterpart center on cytologic atypia, which is absent to minimal in inverted papillomas but invariably present in urothelial carcinoma. Although morphologic overlap does exist between the 2 entities, the inverted papilloma has a favorable prognosis, with little if any malignant potential.

Next

Epidemiology

Inverted papillomas are infrequent and account for less than 1% of urothelial neoplasms.[3, 4] They occur predominantly in men, with a male-to-female ratio of 4-7:1, typically in the 5th to 6th decade of life, although the incidence can range from early adolescence to the mid-90s.[3, 5] Most inverted papillomas are discovered incidentally during routine urologic investigations for bladder outlet obstruction, hematuria, or flank pain. Occasionally inverted papillomas are discovered on follow-up examinations for urothelial malignancies, which in part lends to the discussion regarding their malignant association.

Although the prevalence of urothelial tumors is higher among smokers, this correlation is predominately seen with p53 gene mutations, and consequently, they are associated with higher-grade malignancies.[6, 7] Inverted papillomas have not been shown to harbor p53 gene mutations, though they have been shown to occasionally possess over accumulation of p53 gene products, with one study finding such accumulations in 18.9% of inverted papillomas examined.[4, 8, 9] It should be stressed, thus, that p53 mutations are inherently associated with malignancy but are not intrinsically related to inverted papillomas.

Previous
Next

Etiology

Inverted papillomas arise in the setting of molecular changes that are not fully understood but are genetically distinct from the alterations seen in urothelial carcinoma. Rare cases have been documented regarding malignant transformation of inverted papillomas, but it is unclear whether such cases represent a true transformation, a misclassification of urothelial carcinoma, or inverted papilloma arising in the setting of urothelial carcinoma (and vice versa).[10, 11]

The fibroblast growth factor receptor (FGFR3) gene has been implicated in low-grade urothelial malignancies, and consequently some evidence points toward the involvement of FGFR3 mutations in inverted papillomas, although the evidence is variable and ranges from 9.8% in one study of 62 inverted papillomas[12] to 45% in a study of 20 inverted papillomas.[8]

Previous
Next

Location

The majority (70%) of inverted papillomas occur in the bladder, most often in the trigone, followed by the bladder neck, bladder dome, posterior wall, and lateral wall. The remaining 30% of inverted papillomas occur in the ureter, renal pelvis, and urethra in decreasing frequency.[3]

Previous
Next

Clinical Features and Imaging

The most common symptoms of inverted papillomas, leading to their discovery, are bladder outlet obstruction, hematuria, dysuria, and irritative voiding, with approximately 25% of cases presenting with more than one symptom. Less common symptoms are suprapubic pain and pyuria.

Previous
Next

Gross Findings

Grossly, inverted papillomas are a pedunculated polypoid lesion or a sessile lesion with a smooth surface, covered with grossly normal-appearing urothelial epithelium, and they are usually located in the trigone. Inverted papillomas range in size from a few millimeters to 3 to 4 centimeters in greatest dimension.

Previous
Next

Microscopic Findings

The overall pattern of inverted papillomas is that of cords and trabeculae of urothelial cells that grow into the underlying lamina propria but not the muscularis propria, producing a localized, noninvasive endophytic mass covered by histologically and cytologically normal urothelium. The cords and trabeculae generally contain normal urothelial cells centrally, with darkened, palisading basal cells at the periphery. Rare atypical cells can be found, but these are more of the exception than the rule. Conversely, the more aggressive urothelial carcinoma generally has a thicker, irregularly shaped pattern of cords with transitioning into solid areas, cytologic atypia, nuclear pleomorphism with irregular chromatin distribution, and prominent nucleoli. The general order and peripheral palisading are usually absent in urothelial carcinoma.

Inverted papilloma, low magnification. Inverted papilloma, low magnification. Inverted papilloma, high magnification. Inverted papilloma, high magnification.

Debate arises in the literature pertaining to different subclasses of inverted papillomas, specifically, trabecular and glandular variants; however evidence suggests the glandular subtype is histologically indistinguishable from another urothelial entity, cystitis cystica or glandular cystitis. Other variations, however, are occasionally recognized, including basaloid, hyperplastic, and spindle cell / medullary, in addition to nonkeratinizing or neuroendocrine differentiation.

Previous
Next

Immunohistochemistry

Classic inverted papillomas rarely express the immunohistologic markers of the more worrisome urothelial carcinoma, which include p53, Ki-67, and cytokeratin 20. Whereas inverted papillomas with atypia have been found to occasionally harbor some positivity for p53 and Ki-67, typical inverted papillomas show no immunohistochemical positivity. Scant positivity to immunohistochemical markers should be interpreted in conjunction with cellular features, overall architecture and, if necessary, fluorescence in situ hybridization (FISH) analysis.

Previous
Next

Molecular/Genetics

High-grade urothelial malignancies often harbor mutations of the p53 gene, a tumor suppressor gene known to be influenced by smoking, whereas inverted papillomas have not been shown to consistently exhibit such mutations. Evidence does exist, albeit of variable nature, that inverted papillomas do occasionally possess mutations in the FGFR3 gene, which normally produces a receptor known as the fibroblast growth factor receptor and which is involved in cell signaling.[6, 13]

Very few tumors have been identified that harbor both p53 and FGFR3 mutations, and it has not been definitively answered whether this equates to alternate tumorigenesis pathways or inverted papillomas as a precursor lesion. Supporting separate tumorigenesis are recent developments in molecular testing using FISH assays to detect abnormalities in chromosomes 3, 7, 17, and 21. Such anomalies have been detected in urothelial carcinoma but not in inverted papillomas, supporting the alternate pathogenesis hypothesis. Similar mutations have been identified in loss of heterozygosity (LOH) studies, which consistently exhibit changes found in urothelial carcinoma but not in inverted papilloma.

Previous
Next

Tumor Spread and Staging

The standard treatment for inverted papilloma of the lower urinary tract is transurethral resection (TUR), whereas cases involving the upper urinary tract require various degrees of surgical resection depending on the level of certainty of the behavior of the tumor and whether there is concurrent urothelial carcinoma. The benignity of the lesion precludes any staging.

Previous
Next

Prognosis and Predictive Factors

The prognosis for inverted papilloma is quite good, with a recurrence rate of less than 5%, and the likelihood of synchronous or subsequent development of urothelial carcinoma 6% and 3%, respectively.

Differential Diagnosis

The main consideration in the differential diagnosis is urothelial carcinoma with inverted pattern. Distinction between the two entities can sometimes be difficult histologically due to specimen size, crush and thermal artifact, and general histologic features which overlap, although the amount of cytologic atypia, morphologic and architectural patterns, and mitotic count should be helpful in pointing to a benign or malignant diagnosis.

In cases of difficult histologic discernment, immunohistochemistry can be of assistance, as urothelial carcinoma has positivity for Ki-67, p53, and cytokeratin 20, whereas inverted papillomas generally do not express these markers. Additionally, FISH analysis is capable of detecting chromosomal anomalies that are often present in urothelial carcinoma but absent in inverted papilloma.

Additional considerations include aggregates of von Brunn's nests (distinct nests of solid urothelium within the lamina propria) and inverted papillary urothelial neoplasms of low malignant potential (PUNLMP; similar to von Brunn's nests but with prominent branching). Another entity to keep in mind, particularly in younger patients, is fibroepithelial polyps. Fibroepithelial polyps can present in a manner clinically similar to inverted papillomas and may have a histologically similar appearance, although architecturally fibroepithelial polyps are -- by nature -- exophytic or pedunculated, and display a more dense stroma with fibrovascular cores.

Previous
 
Contributor Information and Disclosures
Author

Joseph Eaton, DO  Resident Physician, Department of Pathology, Indiana University School of Medicine

Joseph Eaton, DO is a member of the following medical societies: American Medical Association, American Society for Clinical Pathology, and College of American Pathologists

Disclosure: Nothing to disclose.

Coauthor(s)

Antonio Lopez-Beltran, MD, PhD  Professor of Anatomic Pathology, Unit of Anatomic Pathology, Department of Surgery, Cordoba University School of Medicine, Spain

Disclosure: Nothing to disclose.

Rodolfo Montironi, MD, FRCPath, IFCAP  Professor of Pathology, Institute of Pathological Anatomy, Polytechnic University of the Marche Region, United Hospitals, Italy; Associate Investigator, University of Arizona College of Medicine

Rodolfo Montironi, MD, FRCPath, IFCAP is a member of the following medical societies: College of American Pathologists, European Society of Pathology, International Society of Urological Pathology, and Royal College of Pathologists

Disclosure: Nothing to disclose.

Liang Cheng, MD  Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Clarian Health Partners

Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, Arthur Purdy Stout Society, College of American Pathologists, International Society of Urological Pathology, and United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Chief Editor

Liang Cheng, MD  Professor of Pathology and Urology, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Clarian Health Partners

Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, Arthur Purdy Stout Society, College of American Pathologists, International Society of Urological Pathology, and United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

References
  1. Potts IF, Hirst E. Inverted papilloma of the bladder. J Urol. Aug 1963;90:175-9. [Medline].

  2. Paschkis R. Uber adenoma der harnblase. Z Urol Chir. 1927;21:315-25.

  3. Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer. Dec 1 2006;107(11):2622-7. [Medline]. [Full Text].

  4. Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol. Oct 2006;19(10):1289-94. [Medline].

  5. Kunze E, Schauer A, Schmitt M. Histology and histogenesis of two different types of inverted urothelial papillomas. Cancer. Jan 15 1983;51(2):348-58. [Medline].

  6. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. Mar 15 2004;64(6):1911-4. [Medline]. [Full Text].

  7. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. Oct 2002;198(2):245-51. [Medline].

  8. Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol. May 2009;22(5):627-32. [Medline].

  9. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol. Sep 1997;21(9):1057-68. [Medline].

  10. Altaffer LF 3rd, Wilkerson SY, Jordan GH, Lynch DF. Malignant inverted papilloma and carcinoma in situ of the bladder. J Urol. Oct 1982;128(4):816-8. [Medline].

  11. Renfer LG, Kelley J, Belville WD. Inverted papilloma of the urinary tract: histogenesis, recurrence and associated malignancy. J Urol. Oct 1988;140(4):832-4. [Medline].

  12. Eiber M, van Oers JM, Zwarthoff EC, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol. Jun 2007;31(6):938-46. [Medline].

  13. van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. Nov 1 2005;11(21):7743-8. [Medline]. [Full Text].

  14. Asano K, Miki J, Maeda S, Naruoka T, Takahashi H, Oishi Y. Clinical studies on inverted papilloma of the urinary tract: report of 48 cases and review of the literature. J Urol. Oct 2003;170(4 Pt 1):1209-12. [Medline].

  15. Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol. Dec 2004;35(12):1499-504. [Medline].

  16. Caro DJ, Tessler A. Inverted papilloma of the bladder: a distinct urological lesion. Cancer. Aug 1978;42(2):708-13. [Medline].

  17. Cheon J, Kim HK, Kim JJ, Yoon DK, Koh SK, Kim IS. Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. J Korean Med Sci. Apr 1995;10(2):103-10. [Medline]. [Full Text].

  18. Fine SW, Chan TY, Epstein JI. Inverted papillomas of the prostatic urethra. Am J Surg Pathol. Aug 2006;30(8):975-9. [Medline].

  19. Grainger R, Gikas PW, Grossman HB. Urothelial carcinoma occurring within an inverted papilloma of the ureter. J Urol. Apr 1990;143(4):802-4. [Medline].

  20. Ho H, Chen YD, Tan PH, Wang M, Lau WK, Cheng C. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience. Urology. Aug 2006;68(2):333-6. [Medline].

  21. Jones TD, Zhang S, Lopez-Beltran A, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol. Dec 2007;31(12):1861-7. [Medline].

  22. Kyriakos M, Royce RK. Multiple simultaneous inverted papillomas of the upper urinary tract. A case report with a review of ureteral and renal pelvic inverted papillomas. Cancer. Jan 15 1989;63(2):368-80. [Medline].

  23. Mattelaer J, Leonard A, Goddeeris P, D'Hoedt M, Van Kerrebroeck P. Inverted papilloma of bladder: clinical significance. Urology. Sep 1988;32(3):192-7. [Medline].

  24. Tsuzuki T, Epstein JI. Fibroepithelial polyp of the lower urinary tract in adults. Am J Surg Pathol. Apr 2005;29(4):460-6. [Medline].

Previous
Next
 
Inverted papilloma, low magnification.
Inverted papilloma, high magnification.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.